American Journal of Ophthalmology
Volume 143, Issue 4 , Pages 601-606.e2 , April 2007

Clinical, Anatomic, and Electrophysiologic Evaluation Following Intravitreal Bevacizumab for Macular Edema in Retinal Vein Occlusion

,Accepted 17 December 2006.

References 

  1. Clarkson JG. Central retinal vein occlusion. In:  Ryan SJ editors. Retina. 3rd ed.. St Louis, Missouri: Mosby; 2001;p. 1368–1375
  2. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central retinal vein occlusion. Arch Ophthalmol. 2002;120:1644–1645
  3. Avastin (Product monograph): Gardiner-Caldwell Communications Mississauga. Ontario: Hoffmann-La Roche Ltd; 2005;
  4. Funatsu H, Yamashita H, Noma H, et al. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol. 2005;243:3–8
  5. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol. 2005;40:352–368
  6. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480–1487
  7. Mulcahy MF, Benson AB. Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther. 2005;5:997–1005
  8. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035–1047
  9. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina. 2006;26:270–274
  10. Marmor MF, Holder GE, Seeliger MW, Yamamoto S. Standard for clinical electroretinography. Doc Ophthalmol. 2004;108:107–114
  11. Marmor MF, Hood DC, Keating D, Kondo M, Seeliger MW, Miyake Y. Guidelines for basic multifocal electroretinography (mfERG). Doc Ophthalmol. 2003;106:105–115
  12. Odom JV, Bach M, Barber C, Brigell M, Marmor MF, Tormene AP, et al. Visual evoked potential standard. Doc Ophthalmol. 2004;108:115–123
  13. Hayreh SS. Classification of central retinal vein occlusion. Ophthalmology. 1983;90:458–474
  14. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005;36:336–339
  15. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin). treatment of macular edema in central retinal vein occlusion: a short-term study. Retina. 2006;26:279–284
  16. Spandau UH, Ihloff AK, Jonas JB. Intravitreal bevacizumab treatment of macular edema due to central retinal vein occlusion. Acta Ophthalmol Scand. 2006;84:555–556[editorial]
  17. Jaissle GB, Ziemssen F, Petermeier K, et al. Bevacizumab for treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe. 2006;103:471–475

PII: S0002-9394(06)01463-2

doi: 10.1016/j.ajo.2006.12.037

American Journal of Ophthalmology
Volume 143, Issue 4 , Pages 601-606.e2 , April 2007

Article Tools

* Image Usage & Resolution